Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone

European Journal of Endocrinology

Volumn 164, Issue 3, 2011, Pages 325-333

  Van Der Lely, Aart Jan ^a   Bernabeu, Ignacio ^b   Cap, Jan ^c   Caron, Philippe ^d   Colao, Annamaria ^e   Marek, Josef ^f   Neggers, Sebastian ^a   Birman, Pascal ^g  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f CHARLES UNIVERSITY   (Czech Republic)

^g IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; PEGVISOMANT; SOMATOMEDIN C; ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; DRUG DERIVATIVE; HORMONE; HUMAN GROWTH HORMONE; SOMATOSTATIN; OCTREOTIDE;

ABDOMINAL PAIN; ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CYTOLYTIC HEPATITIS; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; URTICARIA; VOMITING; ADOLESCENT; BLOOD; CHILD; METABOLISM; MIDDLE AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLADDER STONE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG SUBSTITUTION; ELECTROCARDIOGRAPHY; GLUCOSE TOLERANCE TEST; LIVER FUNCTION TEST; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE;

ACROMEGALY; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHILD; HORMONES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; PEPTIDES, CYCLIC; SOMATOSTATIN; YOUNG ADULT;

EID: 79951996841     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0867     Document Type: Article

References (26)

1. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A & Acromegaly Consensus Group. Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism 2009 94 1509-1517. (doi:10.1210/jc.2008-2421)
2. Murray RD & Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. Journal of Clinical Endocrinology and Metabolism 2008 93 2957-2968. (doi:10.1210/jc.2008-0027)
3. Cook DM, Ezzat S, Katznelson L, Kleinberg DL, Laws ER Jr, Nippoldt TB, Swearingen B, Vance ML & AACE Acromegaly Guidelines Task Force . AACE medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocrine Practice 2004 10 213-225.
4. Goffin V, Bernichtein S, Carrière O, Bennett WF, Kopchick JJ & Kelly PA. The human growth hormone antagonist B2036 does not interact with the prolactin receptor. Endocrinology 1999 140 3853-3856. (doi:10.1210/en.140.8. 3853)
5. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV & Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science 1992 256 1677-1780. (doi:10.1126/science.256.5064.1677)
6. Higham CE, Thomas JD, Bidlingmaier M, Drake WM & Trainer PJ. Successful use of weekly pegvisomant administration in patients with acromegaly. European Journal of Endocrinology 2009 161 21-25. (doi:10.1530/EJE-08-0990)
7. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759. (doi:10.1016/S0140-6736(01)06844-1)
8. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177. (doi:10.1056/NEJM200004203421604)
9. Trainer P. ACROSTUDY: the first 5 years. European Journal of Endocrinology 2009 161 S19-S24. (doi:10.1530/EJE-09-0322)
10. Pfizer Limited. Summary of Product Characteristics: SOMAVERT 10 mg, 15 mg, 20 mg powder and solvent for solution for injection. Available at http://emc.medicines.org.uk/medicine/ 14353/SPC/SOMAVERT (accessed 25 October 2010).
11. Neggers SJ, de Herder WW, Janssen JA, Feelders RA & van der Lely AJ. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. European Journal of Endocrinology 2009 160 529-533. (doi:10.1530/EJE-08-0843)
12. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA & van der Lely AJ. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005 365 1644-1646. (doi:10.1016/S0140-6736(05)63011-5)
13. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C & Ørskov H. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. Journal of Clinical Endocrinology and Metabolism 2005 90 5627-5631. (doi:10.1210/jc.2005- 0531)
14. Attanasio R, Lanzi R, Losa M, Valentini F, Grimaldi F, De Menis E, Davì MV, Battista C, Castello R, Cremonini N, Razzore P, Rosato F, Montini M & Cozzi R. Effects of lanreotide Autogel on growth hormone, insulin-like growth factor I, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocrine Practice 2008 14 846-855.
15. Colao A, Auriemma RS, Rebora A, Galdiero M, Resmini E, Minuto F, Lombardi G, Pivonello R & Ferone D. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clinical Endocrinology 2009 71 237-245. (doi:10.1111/j.1365-2265.2008.03503.x)
16. Mazziotti G & Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 2010 13 60-67. (doi:10.1007/s11102-009-0169-z)
17. Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM & van der Lely AJ. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. Journal of Clinical Endocrinology and Metabolism 2008 93 3853-3859. (doi:10.1210/jc.2008- 0669)
18. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW & van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. Journal of Clinical Endocrinology and Metabolism 2007 92 4598-4601. (doi:10.1210/jc.2007-1234)
19. Kratzch J, Keliner K, Zilkens T, Schmidt-Gayk H, Selisko T & Scholz GH. Growth hormone-binding protein related immunoreactivity is regulated by the degree of insulinopenia in diabetes mellitus. Clinical Endocrinology 1996 44 673-678. (doi:10.1046/j.1365-2265.1996.672494.x)
20. Wurzburger MI, Prelevic GM, Sönksen PH, Wheeler M & Balint-Peric L. Effect of recombinant human growth hormone treatment on insulin-like growth factor (IGF-I) levels in insulin-dependent diabetic patients. Acta Diabetologica 1995 32 131-134. (doi:10.1007/BF00569572)
21. Trainer PJ, Ezzat S, D'Souza GA, Layton G & Strasburger CJ. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clinical Endocrinology 2009 71 549-557. (doi:10.1111/j.1365-2265. 2009.03620.x)
22. Biering H, Saller B, Bauditz J, Pirlich M, Rudolph B, Johne A, Buchfelder M, Mann K, Droste M, Schreiber I, Lochs H, Strasburger CJ & German pegvisomant investigators . Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. European Journal of Endocrinology 2006 154 213-220. (doi:10.1530/eje.1.02079)
23. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ & Lombardi G. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. European Journal of Endocrinology 2006 154 467-477. (doi:10.1530/eje.1.02112)
24. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ & German Pegvisomant Investigators. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. European Journal of Endocrinology 2007 156 75-82. (doi:10.1530/eje.1.02312)
25. Leung KC, Doyle N, Ballesteros M, Waters MJ & Ho KK. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. Journal of Clinical Endocrinology and Metabolism 2000 85 4712-4720. (doi:10.1210/jc.85.12.4712)
26. Moore D, Adi Y, Connock M & Bayliss S. Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocrine Disorders 2009 9 20. (doi:10.1186/1472-6823-9-20)